Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ettore Appella

Showing results (71-80 of 159) with videos related to

Pageof 16
Sort By:
Nature Immunology|March 1, 2005
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinasesJesus M Salvador, Paul R Mittelstadt, Tad Guszczynski, et al.
Biochemistry|February 8, 2006
Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancerYuichiro Higashimoto, Yuya Asanomi, Satoru Takakusagi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitopeThomas K Hoffmann, Douglas J Loftus, Koji Nakano, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263Donald F Hunt, Robert A Henderson, Jeffrey Shabanowitz, et al.
Current HIV Research|July 18, 2006
Preclinical evaluation of a zinc finger inhibitor targeting lentivirus nucleocapsid protein in SIV-infected monkeysMarco L Schito, Adam C Soloff, Danielle Slovitz, et al.
International Journal of Cancer|February 13, 2007
Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neckDaisuke Ito, Carmen Visus, Thomas K Hoffmann, et al.
Bioorganic & Medicinal Chemistry|November 24, 2004
Optimization of unique, uncharged thioesters as inhibitors of HIV replicationPratibha Srivastava, Marco Schito, Rasem J Fattah, et al.
Molecular Cancer Research : MCR|November 21, 2007
Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptideLilian Varricchio, Antimo Migliaccio, Gabriella Castoria, et al.
Biochemistry|January 27, 2009
Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylationLisa M Miller Jenkins, Hiroshi Yamaguchi, Ryo Hayashi, et al.
Biochemistry|March 11, 2015
Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complexLisa M Miller Jenkins, Hanqiao Feng, Stewart R Durell, et al.
Pageof 16

Showing results (71-80 of 159) with videos related to

Sort By:
Pageof 16
Nature Immunology|March 1, 2005
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinasesJesus M Salvador, Paul R Mittelstadt, Tad Guszczynski, et al.
Biochemistry|February 8, 2006
Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancerYuichiro Higashimoto, Yuya Asanomi, Satoru Takakusagi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitopeThomas K Hoffmann, Douglas J Loftus, Koji Nakano, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263Donald F Hunt, Robert A Henderson, Jeffrey Shabanowitz, et al.
Current HIV Research|July 18, 2006
Preclinical evaluation of a zinc finger inhibitor targeting lentivirus nucleocapsid protein in SIV-infected monkeysMarco L Schito, Adam C Soloff, Danielle Slovitz, et al.
International Journal of Cancer|February 13, 2007
Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neckDaisuke Ito, Carmen Visus, Thomas K Hoffmann, et al.
Bioorganic & Medicinal Chemistry|November 24, 2004
Optimization of unique, uncharged thioesters as inhibitors of HIV replicationPratibha Srivastava, Marco Schito, Rasem J Fattah, et al.
Molecular Cancer Research : MCR|November 21, 2007
Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptideLilian Varricchio, Antimo Migliaccio, Gabriella Castoria, et al.
Biochemistry|January 27, 2009
Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylationLisa M Miller Jenkins, Hiroshi Yamaguchi, Ryo Hayashi, et al.
Biochemistry|March 11, 2015
Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complexLisa M Miller Jenkins, Hanqiao Feng, Stewart R Durell, et al.
Pageof 16